Menu
Menu
Hear Dr. Gilles Millat speak about the expansion of cardiogenetic testing and how the SOPHiA DDM™ Cardio Peer Network strengthens variant classification workflows.
Discover how a patient from São Paulo, Brazil, finally found answers after decades of uncertainty thanks to the dedicated efforts of the Bioma Genetics Laboratory.
See how Centre Léon Bérard scaled their cell-free DNA analysis with a tailor-made liquid biopsy solution for mutation detection across cancer types.
We sat down with Prof. Jacques Cadranel, International Coordinator of the DEEP-Lung-IV study and Head of the Pneumology Department at the Hospital Group University Hospitals of Eastern Paris, who shared his experience in this collaboration with SOPHiA GENETICS, and the importance of the integration of multimodal data in clinical practice to advance personalized medicine in lung cancer.
Discover how Bioma Genetics used SOPHiA DDM™ exome solutions to uncover hereditary breast cancer risk and impact early family management.
Discover how A.C. Camargo Cancer Center uses SOPHiA DDM™ to support genetic analysis in hereditary cancer, leading to personalized patient care strategies.
We met with Dr. Sébastien Couraud, DEEP-Lung-IV Scientific Committee member and Head of the Pulmonology and Thoracic Oncology Department at Hospices Civils de Lyon, to talk about his participation in SOPHiA GENETICS’s DEEP-Lung-IV study and reflect on the benefits of multimodal approaches to transform precision medicine and improve patient outcomes. Watch the spotlight: Hello Sébastien, […]
We sat down with Prof. Jean-Christophe Bernhard, UroCCR Coordinator, and Dr. Gaëlle Margue, Urology Fellow, at University Hospital Bordeaux, to discuss the collaboration between UroCCR – the French Kidney Cancer Research Network - and SOPHiA GENETICS, and get their insights on the use of AI-powered multimodal approaches to improve patient care.
We’re excited to shine a spotlight on Elexandra Barboza-Arguedas, who delivered an insightful presentation during our ACMG exhibit theatre session this year. In this interview, she shares deeper insights into her work at the Molecular Diagnostics Laboratory and how the SOPHiA DDM™ Platform is helping her team streamline workflows and uncover critical insights tailored to the unique genetic landscape of the Costa Rican population.
We were glad to host Dr. Davide Martorana, Senior Molecular Geneticist at the Medical Genetic Lab of the University-Hospital of Parma in Italy, who shared with us his institute’s experience with the adoption of the New Generation SOPHiA DDM™ Platform. Read the spotlight:
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.